These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

323 related articles for article (PubMed ID: 32657428)

  • 1. A novel mesenchymal-associated transcriptomic signature for risk-stratification and therapeutic response prediction in colorectal cancer.
    Matsuyama T; Kandimalla R; Ishikawa T; Takahashi N; Yamada Y; Yasuno M; Kinugasa Y; Hansen TF; Fakih M; Uetake H; Győrffy B; Goel A
    Int J Cancer; 2020 Dec; 147(11):3250-3261. PubMed ID: 32657428
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Transcriptomic expression profiling identifies ITGBL1, an epithelial to mesenchymal transition (EMT)-associated gene, is a promising recurrence prediction biomarker in colorectal cancer.
    Matsuyama T; Ishikawa T; Takahashi N; Yamada Y; Yasuno M; Kawano T; Uetake H; Goel A
    Mol Cancer; 2019 Feb; 18(1):19. PubMed ID: 30717807
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An immune, stroma, and epithelial-mesenchymal transition-related signature for predicting recurrence and chemotherapy benefit in stage II-III colorectal cancer.
    Cai D; Wang W; Zhong ME; Fan D; Liu X; Li CH; Huang ZP; Zhu Q; Lv MY; Hu C; Duan X; Wu XJ; Gao F
    Cancer Med; 2023 Apr; 12(7):8924-8936. PubMed ID: 36629124
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification and Construction of Combinatory Cancer Hallmark-Based Gene Signature Sets to Predict Recurrence and Chemotherapy Benefit in Stage II Colorectal Cancer.
    Gao S; Tibiche C; Zou J; Zaman N; Trifiro M; O'Connor-McCourt M; Wang E
    JAMA Oncol; 2016 Jan; 2(1):37-45. PubMed ID: 26502222
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Genome-wide Discovery and Identification of a Novel miRNA Signature for Recurrence Prediction in Stage II and III Colorectal Cancer.
    Kandimalla R; Gao F; Matsuyama T; Ishikawa T; Uetake H; Takahashi N; Yamada Y; Becerra C; Kopetz S; Wang X; Goel A
    Clin Cancer Res; 2018 Aug; 24(16):3867-3877. PubMed ID: 29514841
    [No Abstract]   [Full Text] [Related]  

  • 6. KRT17 as a prognostic biomarker for stage II colorectal cancer.
    Ujiie D; Okayama H; Saito K; Ashizawa M; Thar Min AK; Endo E; Kase K; Yamada L; Kikuchi T; Hanayama H; Fujita S; Sakamoto W; Endo H; Saito M; Mimura K; Saze Z; Momma T; Ohki S; Kono K
    Carcinogenesis; 2020 Jul; 41(5):591-599. PubMed ID: 31754689
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Relative contribution of clinicopathological variables, genomic markers, transcriptomic subtyping and microenvironment features for outcome prediction in stage II/III colorectal cancer.
    Dienstmann R; Villacampa G; Sveen A; Mason MJ; Niedzwiecki D; Nesbakken A; Moreno V; Warren RS; Lothe RA; Guinney J
    Ann Oncol; 2019 Oct; 30(10):1622-1629. PubMed ID: 31504112
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A prognostic index based on an eleven gene signature to predict systemic recurrences in colorectal cancer.
    Kim SK; Kim SY; Kim CW; Roh SA; Ha YJ; Lee JL; Heo H; Cho DH; Lee JS; Kim YS; Kim JC
    Exp Mol Med; 2019 Oct; 51(10):1-12. PubMed ID: 31578316
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunohistochemistry-Based Consensus Molecular Subtypes as a Prognostic and Predictive Biomarker for Adjuvant Chemotherapy in Patients with Stage II Colorectal Cancer.
    Li Y; Yao Q; Zhang L; Mo S; Cai S; Huang D; Peng J
    Oncologist; 2020 Dec; 25(12):e1968-e1979. PubMed ID: 32926498
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Transcriptional signatures for coupled predictions of stage II and III colorectal cancer metastasis and fluorouracil-based adjuvant chemotherapy benefit.
    Song K; Guo Y; Wang X; Cai H; Zheng W; Li N; Song X; Ao L; Guo Z; Zhao W
    FASEB J; 2019 Jan; 33(1):151-162. PubMed ID: 29957060
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A network-based predictive gene-expression signature for adjuvant chemotherapy benefit in stage II colorectal cancer.
    Cao B; Luo L; Feng L; Ma S; Chen T; Ren Y; Zha X; Cheng S; Zhang K; Chen C
    BMC Cancer; 2017 Dec; 17(1):844. PubMed ID: 29237416
    [TBL] [Abstract][Full Text] [Related]  

  • 12. RNA sequencing reveals PNN and KCNQ1OT1 as predictive biomarkers of clinical outcome in stage III colorectal cancer patients treated with adjuvant chemotherapy.
    Mini E; Lapucci A; Perrone G; D'Aurizio R; Napoli C; Brugia M; Landini I; Tassi R; Picariello L; Simi L; Mancini I; Messerini L; Magi A; Pinzani P; Mazzei T; Tonelli F; Nobili S
    Int J Cancer; 2019 Nov; 145(9):2580-2593. PubMed ID: 30973654
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development and Validation of a 15-gene Expression Signature with Superior Prognostic Ability in Stage II Colorectal Cancer.
    Rokavec M; Özcan E; Neumann J; Hermeking H
    Cancer Res Commun; 2023 Aug; 3(8):1689-1700. PubMed ID: 37654625
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serum-based microRNA signature predicts relapse and therapeutic outcome of adjuvant chemotherapy in colorectal cancer patients.
    Ji D; Qiao M; Yao Y; Li M; Chen H; Dong Q; Jia J; Cui X; Li Z; Xia J; Gu J
    EBioMedicine; 2018 Sep; 35():189-197. PubMed ID: 30166271
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic, predictive, and pharmacogenomic assessments of CDX2 refine stratification of colorectal cancer.
    Bruun J; Sveen A; Barros R; Eide PW; Eilertsen I; Kolberg M; Pellinen T; David L; Svindland A; Kallioniemi O; Guren MG; Nesbakken A; Almeida R; Lothe RA
    Mol Oncol; 2018 Sep; 12(9):1639-1655. PubMed ID: 29900672
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of a Novel Five-Gene Signature as a Prognostic and Diagnostic Biomarker in Colorectal Cancers.
    Ghatak S; Mehrabi SF; Mehdawi LM; Satapathy SR; Sjölander A
    Int J Mol Sci; 2022 Jan; 23(2):. PubMed ID: 35054980
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Integrated analysis identifies an immune-based prognostic signature for the mesenchymal identity in colorectal cancer.
    Zhang B; Wang L; Liu Z; Shao B; Jiang W; Shu P
    Medicine (Baltimore); 2020 Jun; 99(25):e20617. PubMed ID: 32569190
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A prognostic six-gene expression risk-score derived from proteomic profiling of the metastatic colorectal cancer secretome.
    Robles J; Pintado-Berninches L; Boukich I; Escudero B; de Los Rios V; Bartolomé RA; Jaén M; Martín-Regalado Á; Fernandez-Aceñero MJ; Imbaud JI; Casal JI
    J Pathol Clin Res; 2022 Nov; 8(6):495-508. PubMed ID: 36134447
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cancer-associated fibroblasts impact the clinical outcome and treatment response in colorectal cancer via immune system modulation: a comprehensive genome-wide analysis.
    Chen YF; Yu ZL; Lv MY; Cai ZR; Zou YF; Lan P; Wu XJ; Gao F
    Mol Med; 2021 Oct; 27(1):139. PubMed ID: 34717544
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of Prognostic Gene Signatures by Developing a scRNA-Seq-Based Integration Approach to Predict Recurrence and Chemotherapy Benefit in Stage II-III Colorectal Cancer.
    Wang Z; Xing K; Zhang B; Zhang Y; Chai T; Geng J; Qin X; Zhang X; Xu C
    Int J Mol Sci; 2022 Oct; 23(20):. PubMed ID: 36293319
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.